Evaluation of isoprinosine to be repurposed as an adjunct anti-tuberculosis chemotherapy
- 1 June 2018
- journal article
- research article
- Published by Elsevier in Medical Hypotheses
- Vol. 115, 77-80
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Modulating immunity as a therapy for bacterial infectionsNature Reviews Microbiology, 2012
- Reduction of Clofazimine by Mycobacterial Type 2 NADH:Quinone OxidoreductaseJournal of Biological Chemistry, 2011
- Short, Highly Effective, and Inexpensive Standardized Treatment of Multidrug-resistant TuberculosisAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Mycobacterium tuberculosis protein kinase K confers survival advantage during early infection in mice and regulates growth in culture and during persistent infection: implications for immune modulationMicrobiology, 2010
- Mycobacterium tuberculosis, macrophages, and the innate immune response: does common variation matter?Immunological Reviews, 2007
- Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequenceNature, 1998
- Inosine PranobexDrugs, 1986
- Isoprinosine enhances the activation of sensitized lymphocytes by Epstein-Barr virus antigensInternational Journal of Immunopharmacology, 1985
- Immunomodulatory activity of isoprinosine on experimental viral infections in avian modelsInternational Journal of Immunopharmacology, 1984
- Isoprinosine increases the antitumor action of interferonInternational Journal of Immunopharmacology, 1979